Lersivirine, administered via oral gavage at doses of 0, 150, 350, and 500 mg/kg daily from gestation days 6 to 17, followed by cesarean section on day 18, induces hepatic metabolizing enzymes initially at 250 mg/kg, later increased to 500 mg/kg/day in mated Crl:CD1(ICR) mice. This treatment is associated with skeletal variations indicative of delayed development and reduced fetal ossifications^[1].

Lersivirine shows remarkable efficacy against extensive panels of both wild type and drug-resistant HIV, aligning with its positive results against isolated RT enzymes^[1].